


Algeria


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Angola

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



0 210 420Km

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Benin

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Botswana

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Burkina Faso

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Burundi

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Cameroon

Schisto haematobium endemicity status


Endemicity status, Program stage

-  0. Non-endemic, Baseline
-  99. Prevalence < 1%, surveillance, Impact
-  1. Low prevalence (< 10%), Baseline
-  11. Prevalence < 10%, Impact
-  2. Moderate prevalence (10%–49%), Baseline
-  21. Prevalence 10%–49%, Impact
-  3. High prevalence ($\geq 50\%$), Baseline
-  31. Prevalence $\geq 50\%$, Impact
-  Not included in analysis
-  Admin 1 boundaries
-  Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Cape Verde

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Central African Republic

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Chad

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Comoros

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence (>= 50%), Baseline
- 31. Prevalence >= 50%, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



0 20 40Km

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Congo

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Congo, DRC


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Cote d'Ivoire

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Equatorial Guinea

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Eritrea


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Ethiopia

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Gabon

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Ghana

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Guinea

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.


Schisto haematobium endemicity status

Endemicity status, Program stage

-

Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Kenya


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Lesotho

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Liberia

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Madagascar


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Malawi

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Mali

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Mauritania

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Mauritius

Schisto haematobium endemicity status

Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



0 90 180Km

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Mozambique

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Namibia

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Niger

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Nigeria

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Rwanda


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Sao Tome & Principe

Schisto haematobium endemicity status

Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



0 25 50Km

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Senegal

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




0 90 180Km

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Seychelles

Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



0 160 320Km

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Sierra Leone

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

South Africa

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

South Sudan

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Eswatini

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Tanzania (Mainland)

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Tanzania (Zanzibar)

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The Gambia

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Togo

Schisto haematobium endemicity status


Endemicity status, Program stage

- 0. Non-endemic, Baseline
- 99. Prevalence < 1%, surveillance, Impact
- 1. Low prevalence (< 10%), Baseline
- 11. Prevalence < 10%, Impact
- 2. Moderate prevalence (10%–49%), Baseline
- 21. Prevalence 10%–49%, Impact
- 3. High prevalence ($\geq 50\%$), Baseline
- 31. Prevalence $\geq 50\%$, Impact
- Not included in analysis
- Admin 1 boundaries
- Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Uganda


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved




The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Zambia


Schisto haematobium endemicity status

Endemicity status, Program stage



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

Zimbabwe

Schisto haematobium endemicity status


Endemicity status, Program stage

-  0. Non-endemic, Baseline
-  99. Prevalence < 1%, surveillance, Impact
-  1. Low prevalence (< 10%), Baseline
-  11. Prevalence < 10%, Impact
-  2. Moderate prevalence (10%–49%), Baseline
-  21. Prevalence 10%–49%, Impact
-  3. High prevalence ($\geq 50\%$), Baseline
-  31. Prevalence $\geq 50\%$, Impact
-  Not included in analysis
-  Admin 1 boundaries
-  Lakes



Data source: DPC/ESPEN
Data as in: October 2024
by DPC/ESPEN
Regional Office for Africa

© World Health Organization 2024
All rights reserved



The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.